Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VFEND I.V · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| VFEND® I.V., Oral | DRUG | - |
| Conventional amphotericin B | DRUG | - |
| Diflucan IV, oral | DRUG | - |
Inclusion Criteria: * Patients with candidemia Exclusion Criteria: * Neutropenia
VFEND I.V is used for candidiasis, a serious fungal infection of the blood. It is a small molecule antifungal drug being developed by Pfizer, Inc. for the treatment of this infectious disease.
VFEND I.V is a small molecule antifungal drug. It is being studied for the treatment of candidiasis, a serious fungal infection of the blood.
VFEND I.V is developed by Pfizer, Inc., a company traded on the New York Stock Exchange under the ticker symbol PFE.
VFEND I.V is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA for the treatment of candidiasis.
VFEND I.V has one completed Phase 3 clinical trial, identified as NCT00163111. This study compared treatment with voriconazole to treatment with amphotericin followed by fluconazole in patients with candidemia, a serious fungal infection of the blood. The trial enrolled 412 participants.
VFEND I.V is a brand name for voriconazole. The clinical trial NCT00163111 compares treatment with voriconazole, which is the active ingredient in VFEND I.V, to other antifungal treatments.